Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNK3 | O14649 | 10/20 | 0.72 |
| ▸ | KCNK9 | Q9NPC2 | 8/20 | 0.72 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.72 |
| ▸ | MEN1 | O00255 | 3/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.68 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.68 |
| ▸ | POLB | P06746 | 1/20 | 0.67 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.63 |
| ▸ | GPR17 | Q13304 | 1/20 | 0.63 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.59 |
| ▸ | NPC1 | O15118 | 2/20 | 0.58 |
| ▸ | RAB9A | P51151 | 2/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19662802 | 0.87 | TP53 (0.68) | KCNK3KCNK9KCNH2MEN1KMT2A | |
| SCHEMBL17818408 | 0.86 | KCNK3 (0.72) | KCNK3KCNK9KCNH2MEN1KMT2A | |
| SCHEMBL2173418 | 0.85 | HTT (0.71) | KCNK3KCNK9MEN1KMT2ANPC1 | |
| SCHEMBL13210705 | 0.85 | NAMPT (0.66) | KCNK3KCNK9MEN1KMT2AMAPK14 | |
| SCHEMBL4253897 | 0.85 | KCNK3 (0.93) | KCNK3KCNK9KCNH2MEN1KMT2A | |
| SCHEMBL259705 | 0.84 | MEN1 (0.65) | KCNK3KCNK9KCNH2MEN1KMT2A | |
| SCHEMBL27383419 | 0.84 | NPC1 (0.63) | P2RY2GPR17NPC1RAB9ATP53 | |
| SCHEMBL8086756 | 0.84 | MAPT (0.50) | KCNK3KCNK9KCNH2MEN1KMT2A | |
| SCHEMBL7335241 | 0.84 | PLAU (0.62) | KCNK3KCNK9KCNH2MEN1KMT2A | |
| SCHEMBL21237393 | 0.82 | LMNA (0.56) | MEN1KMT2ARXFP1MAPK14MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11247989-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2022-02-15 | — | — | US | disclosed |
| EP-3464286-B1 | PYRAZOLOPYRIDINE DERIVATIVES FOR THE TREATMENT OF CANCER | GENENTECH INC (US) | 2021-08-18 | — | — | EP | disclosed |
| US-20190241558-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2019-08-08 | — | — | US | disclosed |
| WO-2017205538-A1 | PYRAZOLOPYRIDINE DERIVATIVES FOR THE TREATMENT OF CANCER | GENENTECH, INC. (US) | 2017-11-30 | — | — | WO | disclosed |
| US-20090036420-A1 | BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | US | disclosed |
| US-20090036420-A1 | BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | US | disclosed |
| US-20090036420-A1 | BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11247989-B2 | Therapeutic compounds and uses thereof | EP300, HDAC1, CREBBP | KCNK3 1817/4885KCNK9 2562/4885KCNH2 2581/4885 |
| US-20090036420-A1 | BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS | GABBR1, GABBR2, CHRM2 | KCNK3 1019/4885KCNK9 1229/4885KCNH2 302/4885 |
| US-20190241558-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | EP300, HDAC1, CREBBP | KCNK3 1817/4885KCNK9 2562/4885KCNH2 2581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.